A first-of-its-kind clinical trial at Children’s Hospital Los Angeles is investigating a novel protocol for neonates with congenital cytomegalovirus (CMV): virus-specific T-cell therapy.The phase 2 randomized trial represents a potentially groundbreaking approach to treating congenital CMV in newborns–which can lead to hearing loss and deafness, developmental delays, vision loss, and more.
